CNLMU Profile
CB
Pharma Acquisition Corp. (CNLMU) is a blank-check company that was
formed for the purpose of acquiring one or more businesses or assets
in the healthcare industry. The company's focus is on identifying
opportunities in the pharmaceuticals, biotechnology, medical devices,
and healthcare services sectors.
As a blank-check company, CB
Pharma Acquisition Corp. has no operating history or revenue, and its
future prospects will depend on the success of its acquisition
strategy. The company has a team of experienced healthcare industry
executives and advisors who will be responsible for identifying and
evaluating potential acquisition targets.
CB Pharma Acquisition
Corp. was founded in 2020 and is based in New York City. The company
went public in December 2020, raising approximately $150 million in
its initial public offering (IPO). As of my knowledge cutoff of
September 2021, there is no further information available about the
company's acquisition plans or potential targets.
CB Pharma
Acquisition Corp. is listed on the NASDAQ stock exchange under the
ticker symbol CNLMU, which includes one share of Class A common stock
and one-half of a redeemable warrant to purchase one share of Class A
common stock. Each whole warrant entitles the holder to purchase one
share of Class A common stock at a price of $11.50 per share. The
warrants are exercisable beginning on the later of 30 days after the
completion of the company's initial business combination or 12 months
from the closing
|
